Koni, Amer A.
Nazzal, Maisa A.
Suwan, Bushra A.
Sobuh, Samah S.
Abuhazeem, Najiya T.
Salman, Asil N.
Salameh, Husam T.
Amer, Riad
Zyoud, Sa’ed H.
Article History
Received: 13 February 2022
Accepted: 9 May 2022
First Online: 14 May 2022
Declarations
:
: All aspects of the study protocol, including access to and use of the patient clinical information, were approved by An-Najah National University’s Institutional Review Board (IRB) (approval number: Pharm July/2020/1) and the Palestinian ministry of health. We fully explained all parts of the study to the patients and obtained their informed verbal consent before starting data collection. The <i>IRB of An-Najah National University</i> approved only verbal consent. Because we did not collect any identifying information during the interview and our study did not pose a major risk to participants, An-Najah National University’s IRB waived the requirement for written informed consent. The authors confirmed that all methods were performed following the relevant guidelines and regulations.
: Not applicable.
: The authors declare that they have no competing interests.